KENT
-
Franchise India Bureau Jul 31 2018 - 2 min readDaiichi Sankyo Company, Limited and Glycotope GmbH have signed a global licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo's proprietary ADC technology with Glycotope's investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Daiichi Sankyo has got global exclusive rights to develop and ...